Benjamin F. Edwards & Company’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-7,942
| Closed | -$225K | – | 2117 |
|
|
2023
Q3 | $225K | Buy |
7,942
+192
| +2% | +$5.44K | 0.01% | 701 |
|
|
2023
Q2 | $234K | Buy |
7,750
+3,116
| +67% | +$94.1K | 0.01% | 690 |
|
|
2023
Q1 | $141K | Buy |
4,634
+57
| +1% | +$1.73K | 0.01% | 811 |
|
|
2022
Q4 | $138K | Sell |
4,577
-112
| -2% | -$3.38K | 0.01% | 808 |
|
|
2022
Q3 | $139K | Sell |
4,689
-29
| -0.6% | -$860 | 0.01% | 774 |
|
|
2022
Q2 | $151K | Buy |
4,718
+59
| +1% | +$1.89K | 0.01% | 744 |
|
|
2022
Q1 | $172K | Buy |
4,659
+818
| +21% | +$30.2K | 0.01% | 724 |
|
|
2021
Q4 | $186K | Buy |
3,841
+281
| +8% | +$13.6K | 0.01% | 709 |
|
|
2021
Q3 | $186K | Sell |
3,560
-241
| -6% | -$12.6K | 0.01% | 681 |
|
|
2021
Q2 | $197K | Buy |
3,801
+80
| +2% | +$4.15K | 0.01% | 650 |
|
|
2021
Q1 | $161K | Sell |
3,721
-358
| -9% | -$15.5K | 0.01% | 725 |
|
|
2020
Q4 | $181K | Sell |
4,079
-223
| -5% | -$9.9K | 0.01% | 671 |
|
|
2020
Q3 | $151K | Buy |
+4,302
| New | +$151K | 0.01% | 656 |
|